Osilodrostat demonstrates sustained responses in patients with Cushing’s disease

More patients treated with osilodrostat achieved normal mUFC after 12 weeks of treatment compared with placebo, according to results from the Phase 3 LINC-4 study. Improvements in mUFC levels were sustained over 36 weeks of treatment in 81% of patients.

Normal mUFC is the primary treatment goal for Cushing’s disease.

“Cushing’s disease is a chronic and debilitating condition that can be extremely challenging to manage and, if left inadequately treated, can have a significant impact on patients’ quality of life and increase the risk of mortality,” said Richard Feelders, MD, Professor of Endocrinology at the Erasmus University Medical Center, Rotterdam, in a press release. “Data from this important Phase III study show that Isturisa (osilodrostat) is an effective and well-tolerated therapy for Cushing’s disease, which significantly reduces and normalizes mUFC levels in most patients. These data are encouraging given the high unmet medical need for patients with this rare disorder.”

Read the full press release here.